Raymond James Trust N.A. Acquires Shares of 67,953 Haleon plc (NYSE:HLN)

Raymond James Trust N.A. acquired a new stake in shares of Haleon plc (NYSE:HLNGet Rating) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 67,953 shares of the company’s stock, valued at approximately $414,000.

A number of other institutional investors have also modified their holdings of HLN. Van ECK Associates Corp acquired a new stake in shares of Haleon during the 3rd quarter valued at about $25,800,000. Douglas Lane & Associates LLC acquired a new stake in shares of Haleon during the 3rd quarter valued at about $14,644,000. Raymond James & Associates acquired a new stake in shares of Haleon during the 3rd quarter valued at about $12,210,000. FNY Investment Advisers LLC acquired a new stake in shares of Haleon during the 3rd quarter valued at about $5,976,000. Finally, GAM Holding AG acquired a new stake in Haleon in the 3rd quarter worth about $5,571,000. Hedge funds and other institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

HLN has been the topic of several research analyst reports. Argus initiated coverage on Haleon in a report on Wednesday, September 28th. They issued a “hold” rating on the stock. Barclays upgraded Haleon from an “equal weight” rating to an “overweight” rating in a report on Wednesday, December 7th. Finally, Morgan Stanley upgraded Haleon from an “equal weight” rating to an “overweight” rating in a report on Friday, January 6th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $298.00.

Haleon Stock Performance

Shares of Haleon stock opened at $7.99 on Friday. The business’s 50 day moving average is $7.38. Haleon plc has a 1-year low of $5.59 and a 1-year high of $8.50.

Haleon Company Profile

(Get Rating)

Haleon plc engages in the research and development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides therapeutic oral health, pain relief, respiratory health, digestive health, and other products, as well as vitamins, minerals, and supplements.

Featured Stories

Institutional Ownership by Quarter for Haleon (NYSE:HLN)

Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.